Susan Galbraith: Five trends will drive the future of cancer treatment

If Susan Galbraith is right, within a decade backbone chemotherapy may have been largely displaced, many more patients will receive curative radiotherapy, and long-term survival benefits in cancer may be radically improved by bringing new treatments into earlier-line therapy and using better screening tools, including some powered by AI.

Galbraith, EVP of oncology R&D at  AstraZeneca plc (LSE:AZN; NASDAQ:AZN), sat down with BioCentury to discuss the past and the future of cancer research, and AstraZeneca’s approach. ...